IL-6 and IL-1β are pivotal targets of antirheumatic agents, and there is evidence that blocking the IL-6 receptor can reduce lung involvement and acute cardiovascular complications in patients with COVID-19 by inhibiting the systemic inflammatory response (106). The gene discussed is IL6; the disease is COVID-19.